These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 27364781)

  • 1. Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer.
    Lin WC; Westphalen AC; Silva GE; Chodraui Filho S; Reis RB; Muglia VF
    Abdom Radiol (NY); 2016 Nov; 41(11):2209-2217. PubMed ID: 27364781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes.
    Abreu-Gomez J; Walker D; Alotaibi T; McInnes MDF; Flood TA; Schieda N
    Eur Radiol; 2020 Aug; 30(8):4251-4261. PubMed ID: 32211965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI-RADS v2 and ADC values: is there room for improvement?
    Jordan EJ; Fiske C; Zagoria R; Westphalen AC
    Abdom Radiol (NY); 2018 Nov; 43(11):3109-3116. PubMed ID: 29550953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
    Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
    Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI-RADS v2.
    Yim JH; Kim CK; Kim JH
    J Magn Reson Imaging; 2018 Apr; 47(4):1072-1079. PubMed ID: 28901655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
    Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
    Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of relationships between the final Gleason score, PI-RADS v2 score, ADC value, PSA level, and tumor diameter in patients that underwent radical prostatectomy due to prostate cancer.
    Gündoğdu E; Emekli E; Kebapçı M
    Radiol Med; 2020 Sep; 125(9):827-837. PubMed ID: 32266690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Diffusion Kurtosis Imaging Versus Standard Diffusion Imaging for Detection and Grading of Peripheral Zone Prostate Cancer.
    Roethke MC; Kuder TA; Kuru TH; Fenchel M; Hadaschik BA; Laun FB; Schlemmer HP; Stieltjes B
    Invest Radiol; 2015 Aug; 50(8):483-9. PubMed ID: 25867657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Value Analysis of PI-RADS v2.1 Combined with ADC Values in the Risk Stratification of Prostate Cancer Gleason Scores: A Retrospective Study.
    Wang W; Zhu M; Luo Z; Li F; Wan C; Zhu L
    Arch Esp Urol; 2024 Sep; 77(8):889-896. PubMed ID: 39385484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
    Krishna S; McInnes M; Lim C; Lim R; Hakim SW; Flood TA; Schieda N
    AJR Am J Roentgenol; 2017 Dec; 209(6):W365-W373. PubMed ID: 28981356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination of prostate imaging reporting and data system 
with the apparent diffusion coefficient map for the diagnosis of peripheral zone prostate cancer].
    Feng Z; Yan Z; Luo M; Liao Y; Rong P; Wang W
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Mar; 44(3):277-284. PubMed ID: 30971520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Utility of PI-RADS 2.1, ADC Values, and Combined Use of Both, for the Diagnosis of Transition Zone Prostate Cancers.
    Liu X; Xiong Q; Zeng W; Yang R; Wen Y; Li X
    J Comput Assist Tomogr; 2024 Mar-Apr 01; 48(2):206-211. PubMed ID: 38149651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient.
    Donati OF; Mazaheri Y; Afaq A; Vargas HA; Zheng J; Moskowitz CS; Hricak H; Akin O
    Radiology; 2014 Apr; 271(1):143-52. PubMed ID: 24475824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
    Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
    Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiparametric MRI of the prostate: diagnostic performance and interreader agreement of two scoring systems.
    Lin WC; Muglia VF; Silva GE; Chodraui Filho S; Reis RB; Westphalen AC
    Br J Radiol; 2016 Jun; 89(1062):20151056. PubMed ID: 27007818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Weighted Diffusion Subtraction for Detection of Clinically Significant Prostate Cancer.
    Sato T; Isoda H; Fujimoto K; Furuta A; Fujimoto M; Ito K; Kobayashi T; Nakamoto Y
    J Magn Reson Imaging; 2021 Dec; 54(6):1979-1988. PubMed ID: 34085328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.
    Tavakoli AA; Hielscher T; Badura P; Görtz M; Kuder TA; Gnirs R; Schwab C; Hohenfellner M; Schlemmer HP; Bonekamp D
    Radiology; 2023 Jan; 306(1):186-199. PubMed ID: 35972360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of PI-RADS v2 for the Detection of Prostate Cancer.
    Kasel-Seibert M; Lehmann T; Aschenbach R; Guettler FV; Abubrig M; Grimm MO; Teichgraeber U; Franiel T
    Eur J Radiol; 2016 Apr; 85(4):726-31. PubMed ID: 26971415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
    Chen T; Li M; Gu Y; Zhang Y; Yang S; Wei C; Wu J; Li X; Zhao W; Shen J
    J Magn Reson Imaging; 2019 Mar; 49(3):875-884. PubMed ID: 30230108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.